BACKGROUND: Although the short-term adverse effects of @entity2857 are well known, few data exist on long-term @entity137 . The objective of the present study was to investigate the prevalence of @entity788 among a cohort of @entity1 with @entity157 ( @entity157 ) who were treated with @entity2857 for >= 2  y. METHODS: Between March 2007 and December 2013, 31 @entity1 with @entity157 who were treated with @entity2857 for >= 2  y were identified. The effect of @entity788 and enhancement on incidence of adverse events, @entity5 response, and @entity1349 ( @entity1349 ) were assessed. RESULTS: Thirty-one @entity1 with @entity157 were treated with @entity2857 for >= 2  y and met inclusion criteria; 11 @entity1 (35.5%) were @entity96 stage B, whereas 20 @entity1 (64.5%) were @entity96 stage C. Median duration of treatment with @entity2857 was 35.2  mo. @entity788 and a decrease in pancreatic enhancement occurred in 24 @entity1 (77.4%) and 15 @entity1 (48.4%), respectively. On the basis of the modified response evaluation criteria in solid @entity5 , four @entity1 (12.9%) had a complete response, 10 @entity1 (32.3%) had a partial response, and 17 @entity1 (54.8%) had stable disease. @entity1 treated with @entity2857 with @entity788 had a median @entity1349 of 49.4  mo (95% confidence interval, 41.2-57.5  mo) compared with 31.2  mo (95% confidence interval, 25.7-36.7  mo) among @entity1 who did not develop @entity788 (P  =  0.009). In contrast, survival was not associated with decreased versus normal enhancement @entity788 ( @entity1349 , 47.7  mo versus 41.7  mo, respectively; P  =  0.739). CONCLUSIONS: @entity788 occurred in many @entity157 @entity1 after 2  y of treatment with  @entity2857 . @entity1 who experienced @entity788 had a better @entity5 response and @entity1349 .

Long-term therapy with @entity2857 is associated with XXXX .

@entity1 :: ('9606', 'Species') :: ['Patients', 'patients'] @entity788 :: ('MESH:D010190', 'Disease') :: ['Pancreatic atrophy', 'of the pancreas', 'pancreatic atrophy'] @entity137 :: ('MESH:D064420', 'Disease') :: ['toxicity'] @entity96 :: ('MESH:D008113', 'Disease') :: ['Barcelona-clinic liver cancer'] @entity5 :: ('MESH:D009369', 'Disease') :: ['tumor', 'tumors'] @entity2857 :: ('MESH:C471405', 'Chemical') :: ['sorafenib'] @entity157 :: ('MESH:D006528', 'Disease') :: ['HCC', 'hepatocellular carcinoma'] @entity1349 :: ('MESH:D011475', 'Disease') :: ['OS', 'overall survival']
@entity788 :: (MESH:D010190,Disease) :: ['pancreatic atrophy']
